Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
Correlates of protection against SARS-CoV-2 in rhesus macaques
Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters
Approaches and Challenges in SARS-CoV-2 Vaccine Development
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
SARS-CoV-2 infection protects against rechallenge in rhesus macaques
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
Lack of therapeutic efficacy of an antibody to α4β7 in SIVmac251-infected rhesus macaques.
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
Evidence that CD32a does not mark the HIV-1 latent reservoir.
Fetal neuropathology in Zika virus-infected pregnant female rhesus monkeys.
Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys
Zika virus persistence in the central nervous system and lymph nodes of rhesus monkeys.
Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys.
Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus.
Cryo-EM reveals a novel octameric integrase structure for betaretroviral intasome function.
Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys.
Vaccine protection against Zika virus from Brazil.
Zika viral dynamics and shedding in rhesus and cynomolgus macaques.
Rapid inflammasome activation following mucosal SIV infection of rhesus monkeys.
Antigen-specific NK cell memory in rhesus macaques.
Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys.
NYMAG
NYT
Boston Globe
wsj
